Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
12:30pm, Wednesday, 03'rd Jun 2026
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
12:30pm, Wednesday, 03'rd Jun 2026
CRISPR's Casgevy cements the company as a leader in gene-editing therapies. The company's commercial momentum should build as Casgevy reaches more patients.
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
03:00am, Wednesday, 03'rd Jun 2026
Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
12:30pm, Monday, 01'st Jun 2026
This little-discussed pipeline program could prove to be a big success.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 01'st Jun 2026
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
12:11pm, Sunday, 31'st May 2026
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Thursday, 28'th May 2026
ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the followin
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
05:40pm, Thursday, 21'st May 2026
Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 19'th May 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The Best Stocks to Invest $3,000 In Right Now
09:45am, Tuesday, 19'th May 2026
Not every high-potential name costs a fortune to step into.
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
08:14pm, Friday, 15'th May 2026
CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from mult
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:50pm, Tuesday, 12'th May 2026
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
04:15pm, Monday, 11'th May 2026
The biotech's innovative platform could pay off.
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
02:21pm, Friday, 08'th May 2026
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
